Cometriq® approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved Cometriq®...

Read more

New website for Sobi Partner Products

Sobi Partner Products launches new website

Read more

Sobi gains rights to distribute RAVICTI® on a named patient use basis in Middle East from Hyperion Therapeutics, Inc.

Stockholm, Sweden and South San Francisco, CA -- October 1, 2013 -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Hyperion Therapeutics,...

Read more

Sobi gains rights to distribute RAVICTI® on a named patient use basis in Middle East from Hyperion Therapeutics, Inc.

Stockholm, Sweden and South San Francisco, CA -- October 1, 2013 -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Hyperion Therapeutics,...

Read more

Auxilium Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) enter a collaboration agreement for XIAPEX® in 71 Eurasian and African countries

-Sobi Obtains Exclusive Rights for One Commercial and One Development Indication for XIAPEX-
-In Addition to Royalties, Auxilium to Receive up to $40 M...

Read more

Auxilium Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) enter a collaboration agreement for XIAPEX® in 71 Eurasian and African countries

-Sobi Obtains Exclusive Rights for One Commercial and One Development Indication for XIAPEX-
-In Addition to Royalties, Auxilium to Receive up to $40 M...

Read more

EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM

EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER

Read more

EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM

EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER

Read more

Sobi gains distribution rights for Megace®, Monopril®, Cefzil® and Duricef® from PharmaSwiss

Sobi gains distribution rights for Megace®, Monopril®, Cefzil® and Duricef® from PharmaSwiss

Read more

Sobi gains distribution rights for Megace®, Monopril®, Cefzil® and Duricef® from PharmaSwiss

Sobi gains distribution rights for Megace®, Monopril®, Cefzil® and Duricef® from PharmaSwiss

Read more